Psychedelic Research Recap November 2022
In November, we got results of COMPASS Pathways Phase II trial, antidepressants were found to weaken the effects of psilocybin while ketanserin has the potential to stop an LSD trip.
november 2022
The Severe Lack of Long-Term Psychedelic Studies
212 people that have gone through psychedelic trials for which we have data that extends beyond 3 months. We need more data if we want psychedelic-assisted therapy (PAT) to scale.
EAGx Rotterdam Fireside Chat – Psychedelics as Medicines
How can psychedelics become medicines through the effective altruism lens. A transcript of a fireside chat at EAGx Rotterdam.
Psychedelic Research Links November 2022
This is all the other psychedelic research that came out in November 2022. These papers don’t (yet) have their own page in our database.
Blossom Update – November 2022
November will be another month of continued building for Blossom. Dynamic visualisations, paper summaries, courses incoming.
Psychedelic Research Recap October 2022
In October, natural language processing (NLP) was used to successfully predict clinical outcomes using data from a trial exploring psilocybin on treatment-resistant depression (TRD). The first real-world study assessing esketamine for TRD yielded positive results, while new evidence suggests people who microdose may build a tolerance which needs to be taken in future trials.